Rising Pharma Holding, Inc. FDA Inspection Record

FEI 3015784623 · Inspections, Form 483s, warning letters and import refusals

Rising Pharma Holding, Inc. is an FDA-inspected facility (FEI 3015784623) located in East Brunswick, NJ, US. RegDataLab tracks 1 FDA inspection at this facility.

What FDA found at this site

Latest inspection
Nov 3, 2023: No Action Indicated (NAI)
Inspections on record
1 (1 NAI)
Last OAI inspection
None on record
Warning letters
None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
Recalls as the recalling firm
12, latest Jul 13, 2026
Import refusals
2

A Form 483 lists an inspector's observations. OAI means FDA recommends regulatory and/or administrative action. A warning letter is FDA's formal enforcement notice. No record here does not establish that a site is safe. Check this site on FDA's Data Dashboard.

Inspections and what FDA cited

Newest first. Citations are the inspector observations FDA publishes for the inspection.

DateResultWhat FDA cited
Nov 3, 2023No Action Indicated (NAI)No citations listed

Recalls

Showing the 10 most recent of 12 recalls. Recalls FDA's Enforcement Report lists with this FEI as the recalling firm. The recalling firm is not always the site that made the product. Search FDA's Enforcement Report by recall number.

DateClassRecallProduct and reason
Jul 13, 2026Class IID-0724-2026Rising, Cyproheptadine Hydrochloride Syrup, 2mg/5 mL, 473 mL (ONE PINT), Rx only…
Presence of Precipitate: medication was crystallizing and particles floating in the bottle
Mar 3, 2026Class IID-0384-2026Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only…
Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing
Oct 7, 2025Class IID-0029-2026Carbidopa, Levodopa, Entacapone Tablets, 25 mg/100 mg/200 mg, 100-count bottle, Rx Only…
Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5…
Mar 5, 2025Class IID-0277-2025Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000-count bottle, Rx only, Distributed…
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Dec 30, 2024Class IID-0188-2025Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000… and 2 more products
CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Nov 19, 2024Class IID-0105-2025Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by… and 2 more products
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
Jun 24, 2024Class IIID-0599-2024Diflorasone Diacetate Ointment, USP, 0.05%, 60g tube, Rx only, Mfd. By: Lyne Laboratories…
Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification…
May 16, 2024Class IIID-0541-2024Pregabalin Capsules 50mg, 1000-count bottle, Rx Only, Manufactured for: Rising Pharma…
Presence of Foreign Tablets/Capsules: Complaint received from a re-packager, American Health Packaging (AHP), where a foreign tablet was…
Dec 29, 2023Class IID-0222-2024buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx…
Presence of Foreign Tablets/Capsules
Feb 15, 2023Class IID-0348-2023Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising…
Failed Impurities/Degradation Specifications

FDA record score

32 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.

Counted on Nov 16, 2026, method version 1. It counts records and does not judge the site: a low number does not establish that a site is safe, and sites that FDA inspects more often can collect more points. How this is counted.

10 records behind this number
RecordDatePoints x age weightAdds
Class II recall D-0724-2026, this FEI as the recalling firmJul 13, 20264 x 14
Class II recall D-0384-2026, this FEI as the recalling firmMar 3, 20264 x 14
Class II recall D-0029-2026, this FEI as the recalling firmOct 7, 20254 x 14
Class II recall D-0277-2025, this FEI as the recalling firmMar 5, 20254 x 14
Class II recall D-0188-2025, this FEI as the recalling firmDec 30, 20244 x 14
Class II recall D-0105-2025, this FEI as the recalling firmNov 19, 20244 x 14
Class II recall D-0222-2024, this FEI as the recalling firmDec 29, 20234 x 0.62.4
Class II recall D-0348-2023, this FEI as the recalling firmFeb 15, 20234 x 0.62.4
Class II recall D-0573-2022, this FEI as the recalling firmFeb 7, 20224 x 0.62.4
Class II recall D-0005-2022, this FEI as the recalling firmSep 2, 20214 x 0.251

When each source was last refreshed

FDA sources behind this page and when RegDataLab last refreshed each one
RecordsLast refreshedSource as ofStatus
InspectionsNov 16, 2026Newest record Nov 5, 2026Current
Inspection citationsNov 16, 2026Newest record Nov 5, 2026Current
Compliance actions (warning letters, injunctions and other action types)Nov 2, 2026Newest record Oct 29, 2026Current
Warning letter textNov 16, 2026Newest record Nov 10, 2026Current
Recalls (Enforcement Report)Nov 16, 2026Newest record Nov 11, 2026Current
Form 483s and inspection documentsNov 13, 2026Newest record Nov 12, 2026Current
Import refusalsNov 15, 2026Newest record Nov 5, 2026Current

Reviewing Rising Pharma Holding, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Rising Pharma Holding, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Facility details

Company
Rising Pharma Holding, Inc.
Location
East Brunswick, NJ (US)
Source
inspections

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.